Detalhe da pesquisa
1.
Efficacy and safety of co-administered once-weekly cagrilintide 2·4 mg with once-weekly semaglutide 2·4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial.
Lancet
; 402(10403): 720-730, 2023 08 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-37364590
2.
Efficacy and safety of once-daily oral semaglutide 25 mg and 50 mg compared with 14 mg in adults with type 2 diabetes (PIONEER PLUS): a multicentre, randomised, phase 3b trial.
Lancet
; 402(10403): 693-704, 2023 08 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-37385279
3.
Relationship between body weight change and glycaemic control with tirzepatide treatment in people with type 2 diabetes: A post hoc assessment of the SURPASS clinical trial programme.
Diabetes Obes Metab
; 25(9): 2553-2560, 2023 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-37246796
4.
Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial.
Lancet
; 398(10317): 2160-2172, 2021 12 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-34798060
5.
Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial.
Lancet
; 397(10278): 971-984, 2021 03 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-33667417
6.
Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.
N Engl J Med
; 381(9): 841-851, 2019 08 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-31185157
7.
Gastrointestinal tolerability of once-weekly semaglutide 2.4 mg in adults with overweight or obesity, and the relationship between gastrointestinal adverse events and weight loss.
Diabetes Obes Metab
; 24(1): 94-105, 2022 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34514682
8.
The role of icosapent ethyl in cardiovascular risk reduction.
Curr Opin Cardiol
; 36(5): 661-671, 2021 09 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33929367
9.
Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial.
Lancet
; 392(10148): 637-649, 2018 08 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-30122305
10.
Cardiovascular safety of oral semaglutide in patients with type 2 diabetes: Rationale, design and patient baseline characteristics for the PIONEER 6 trial.
Diabetes Obes Metab
; 21(3): 499-508, 2019 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-30284349
11.
Effects of PYY3-36 and GLP-1 on energy intake, energy expenditure, and appetite in overweight men.
Am J Physiol Endocrinol Metab
; 306(11): E1248-56, 2014 Jun 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-24735885
12.
Management of type 2 diabetes, obesity, or nonalcoholic steatohepatitis with high-dose GLP-1 receptor agonists and GLP-1 receptor-based co-agonists.
Obes Rev
; 25(3): e13663, 2024 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-37968541
13.
Review of an international pilot project to adapt the Canadian Adult Obesity Clinical Practice Guideline.
Obes Pillars
; 8: 100090, 2023 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-38125658
14.
Managing the gastrointestinal side effects of GLP-1 receptor agonists in obesity: recommendations for clinical practice.
Postgrad Med
; 134(1): 14-19, 2022 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-34775881
15.
Persons With Diabetes and General/Family Practitioner Perspectives Related to Therapeutic Inertia in Type 2 Diabetes Mellitus Using Qualitative Focus Groups and the Theoretical Domains Framework: Results From the MOTION Study.
Can J Diabetes
; 46(2): 171-180, 2022 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-35288041
16.
A Cross-sectional Survey to Assess Reasons for Therapeutic Inertia in People With Type 2 Diabetes Mellitus and Preferred Strategies to Overcome It From the Perspectives of Persons With Diabetes and General/Family Practitioners: Results From the MOTION Study.
Can J Diabetes
; 46(4): 337-345.e2, 2022 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-35527203
17.
Comparison of 150-mm versus 100-mm visual analogue scales in free living adult subjects.
Appetite
; 54(3): 583-6, 2010 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-20138943
18.
Efficacy and Safety of Liraglutide 3.0 mg in Individuals With Overweight or Obesity and Type 2 Diabetes Treated With Basal Insulin: The SCALE Insulin Randomized Controlled Trial.
Diabetes Care
; 43(5): 1085-1093, 2020 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-32139381
19.
Perceptions of barriers to effective obesity management in Canada: Results from the ACTION study.
Clin Obes
; 9(5): e12329, 2019 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-31294535
20.
Portion control plate for weight loss in obese patients with type 2 diabetes mellitus: a controlled clinical trial.
Arch Intern Med
; 167(12): 1277-83, 2007 Jun 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-17592101